Hledání v detailu akcií
Top akcie
NázevNávštěvy
31 150
1 248
1 134
1 034
932
677
543
518
373
365
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,38
KB-1,24
PKN109,35106,2-0,05
Msft2,55
IBM-0,97
DCX70,9570,980,17
PFE2,03
16.12.2017 2:10:00
Indexy online
AD Index online
select
AD Index online
 

  • 15.12.2017
Novo Nordisk -B- (Frankfurt)
Závěr k 15.12.2017 Změna (%) Změna (EUR) Objem obchodů (EUR)
44,59 -0,40 -0,18 1 140 561
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 16.12.2017
Popis společnosti
Obecné informace
Název společnostiNovo Nordisk A/S
TickerNOVO B
Kmenové akcie:Ordinary Shares Class B
Kmenové akcie:Ordinary Shares Class A
RICNOVOb.CO
ISINDK0060534915
Poslední známé roční výsledky31.12.2016
Poslední známé čtvrtletní výsledky30.9.2017
Počet zaměstnanců k 30.9.2017 41 656
Akcie v oběhu k 30.9.20172 504 332 748
MěnaDKK
Kontaktní informace
UliceNovo Alle
MěstoBAGSVAERD
PSČ2880
ZeměDenmark
Kontatní osobaPeter Hugreffe Ankersen
Funkce kontaktní osobyCorporate Vice President & Head of Investor Relations
Telefon4 544 448 888
Fax4544436633

Business Summary: Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Financial Summary: BRIEF: For the nine months ended 30 September 2017, Novo Nordisk A/S revenues increased 2% to DKR83.7B. Net income increased 2% to DKR29.88B. Revenues reflect Diabetes Care segment increase of 7% to DKR69.73B, Europe segment increase of 2% to DKR15.77B, Region China segment increase of 4% to DKR8.2B, USA segment increase of less than 1% to DKR41.95B. Net income also reflects Diabetes Care segment income increase of 11% to DKR30.66B.
Odvětvová klasifikace
TRBC2012Pharmaceuticals - NEC
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSMedicinal and Botanical Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICMedicinals And Botanicals
SICCommercial Physical Research



  • Poslední aktualizace: 16.12.2017
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardGoran Ando6820.3.20138.3.2006
President, Chief Executive OfficerLars Fruergaard Joergensen501.1.2017
Vice Chairman of the BoardJeppe Christiansen5720.3.201320.3.2013
Chief Financial Officer, Executive Vice PresidentJesper Brandgaard541.1.1999
Executive Vice President, International OperationsMaziar Doustdar46
Chief Science Officer, Executive Vice PresidentMads Krogsgaard Thomsen56
Executive Vice President, North America OperationsDoug Langa-15.8.20171.3.2017
Executive Vice President, Commercial Strategy & Corporate AffairsCamilla Sylvest-1.10.20171.10.2017
Executive Vice President, Product SupplyHenrik Wulff47